Quanterix reported fourth-quarter revenue of $43.9 million, up 25% year-on-year and 7% sequentially, driven by stronger-than-expected academic demand. The company holds approximately $122 million in cash and guided 2026 revenue of $169–174 million whilst targeting cash-flow break-even in the second half of 2026. New CEO Everett Cunningham outlined a diversification strategy, with roughly 60% neurology and 40% spatial biology, oncology and immunology. Management has implemented $74 million of an $85 million cost-synergy target. Quanterix's LucentAD diagnostic received a $897 CMS reimbursement rate. The company submitted a 510(k) application in January 2026, expecting approval by Q4 2026 following a six to nine-month review. Clinical utility study results are anticipated in H2 2026.

Quanterix Corporation reported fourth-quarter revenue of $43.9 million, up 25% year-over-year, exceeding expectations. Full-year 2025 revenue reached $138.9 million, a 1% increase from 2024. The biomarker detection company ended the quarter with $121.6 million in cash and equivalents. Fourth-quarter adjusted cash usage was $3.0 million, whilst full-year adjusted cash usage totalled $30.9 million. In January 2026, Quanterix submitted a 510(k) application to the FDA for its Alzheimer's disease blood test. The Centers for Medicare & Medicaid Services established a $897 reimbursement rate for its LucentAD Complete test. For 2026, the company expects revenue between $169 million and $174 million, with adjusted gross margin of 49% to 53%. Quanterix anticipates achieving cash flow breakeven in the second half of 2026.